In vitro antibacterial properties of pexiganan, an analog of magainin
- PMID: 10103181
- PMCID: PMC89207
- DOI: 10.1128/AAC.43.4.782
In vitro antibacterial properties of pexiganan, an analog of magainin
Abstract
Pexiganan, a 22-amino-acid antimicrobial peptide, is an analog of the magainin peptides isolated from the skin of the African clawed frog. Pexiganan exhibited in vitro broad-spectrum antibacterial activity when it was tested against 3,109 clinical isolates of gram-positive and gram-negative, anaerobic and aerobic bacteria. The pexiganan MIC at which 90% of isolates are inhibited (MIC90) was 32 micrograms/ml or less for Staphylococcus spp., Streptococcus spp., Enterococcus faecium, Corynebacterium spp., Pseudomonas spp., Acinetobacter spp., Stenotrophomonas spp., certain species of the family Enterobacteriaceae, Bacteroides spp., Peptostreptococcus spp., and Propionibacterium spp. Comparison of the MICs and minimum bactericidal concentrations (MBCs) of pexiganan for 143 isolates representing 32 species demonstrated that for 92% of the isolates tested, MBCs were the same or within 1 twofold difference of the MICs, consistent with a bactericidal mechanism of action. Killing curve analysis showed that pexiganan killed Pseudomonas aeruginosa rapidly, with 10(6) organisms/ml eliminated within 20 min of treatment with 16 micrograms of pexiganan per ml. No evidence of cross-resistance to a number of other antibiotic classes was observed, as determined by the equivalence of the MIC50s and the MIC90s of pexiganan for strains resistant to oxacillin, cefazolin, cefoxitin, imipenem, ofloxacin, ciprofloxacin, gentamicin, and clindamicin versus those for strains susceptible to these antimicrobial agents. Attempts to generate resistance in several bacterial species through repeated passage with subinhibitory concentrations of pexiganan were unsuccessful. In conclusion, pexiganan exhibits properties in vitro which make it an attractive candidate for development as a topical antimicrobial agent.
Figures

Similar articles
-
In vitro susceptibility to pexiganan of bacteria isolated from infected diabetic foot ulcers.Diagn Microbiol Infect Dis. 1999 Sep;35(1):45-53. doi: 10.1016/s0732-8893(99)00056-5. Diagn Microbiol Infect Dis. 1999. PMID: 10529881
-
In vitro spectrum of pexiganan activity; bactericidal action and resistance selection tested against pathogens with elevated MIC values to topical agents.Diagn Microbiol Infect Dis. 2016 Sep;86(1):66-9. doi: 10.1016/j.diagmicrobio.2016.06.012. Epub 2016 Jun 16. Diagn Microbiol Infect Dis. 2016. PMID: 27352729
-
In vitro spectrum of pexiganan activity when tested against pathogens from diabetic foot infections and with selected resistance mechanisms.Antimicrob Agents Chemother. 2015 Mar;59(3):1751-4. doi: 10.1128/AAC.04773-14. Epub 2015 Jan 12. Antimicrob Agents Chemother. 2015. PMID: 25583717 Free PMC article.
-
Pexiganan acetate.Drugs. 1998 Dec;56(6):1047-52; discussion 1053-4. doi: 10.2165/00003495-199856060-00011. Drugs. 1998. PMID: 9878992 Review.
-
A review of the in vitro activity of meropenem and comparative antimicrobial agents tested against 30,254 aerobic and anaerobic pathogens isolated world wide.Diagn Microbiol Infect Dis. 1997 Aug;28(4):157-63. doi: 10.1016/s0732-8893(97)00065-5. Diagn Microbiol Infect Dis. 1997. PMID: 9327242 Review.
Cited by
-
Antibacterial properties of dermaseptin S4 derivatives under extreme incubation conditions.Antimicrob Agents Chemother. 2006 Feb;50(2):490-7. doi: 10.1128/AAC.50.2.490-497.2006. Antimicrob Agents Chemother. 2006. PMID: 16436701 Free PMC article.
-
Experimental evolution of resistance to an antimicrobial peptide.Proc Biol Sci. 2006 Jan 22;273(1583):251-6. doi: 10.1098/rspb.2005.3301. Proc Biol Sci. 2006. PMID: 16555795 Free PMC article.
-
Antimicrobial Peptides: A New Hope in Biomedical and Pharmaceutical Fields.Front Cell Infect Microbiol. 2021 Jun 14;11:668632. doi: 10.3389/fcimb.2021.668632. eCollection 2021. Front Cell Infect Microbiol. 2021. PMID: 34195099 Free PMC article. Review.
-
Antimicrobial peptides and wound healing: biological and therapeutic considerations.Exp Dermatol. 2016 Mar;25(3):167-73. doi: 10.1111/exd.12929. Epub 2016 Feb 10. Exp Dermatol. 2016. PMID: 26738772 Free PMC article. Review.
-
Synthetic mimics of antimicrobial peptides from triaryl scaffolds.J Med Chem. 2011 Apr 14;54(7):2241-54. doi: 10.1021/jm101410t. Epub 2011 Mar 9. J Med Chem. 2011. PMID: 21388190 Free PMC article.
References
-
- Bessalle R, Kapitkovshy A, Gorea A, Shalit I, Fridkin M. All d-magainin: chirality antimicrobial activity, and proteolytic resistance. FEBS Lett. 1990;274:151–155. - PubMed
-
- Boman H G. Peptide antibiotics and their role in innate immunity. Annu Rev Immunol. 1995;13:61–92. - PubMed
-
- Groisman E A. How bacteria resist killing by host-defense peptides. Trends Microbiol. 1994;2:444–449. - PubMed
-
- Groisman E A, Aspedon A. The genetic basis of microbial resistance to antimicrobial peptides. Methods Mol Biol. 1995;78:205–215. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous